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Abstract
Background—Current guidelines recommend that all sexually active HIV-infected persons be 
tested at least annually for syphilis, chlamydia, and gonorrhea. We examined temporal trends in 
syphilis, chlamydia, and gonorrhea testing among sexually active HIV-infected adults receiving 
medical care in the United States during 2009–2013.
Methods—Using medical record data from the Medical Monitoring Project, a population-based 
HIV surveillance system, we assessed the proportion of adults in HIV medical care who were 
tested for syphilis, chlamydia, and gonorrhea in the past 12 months by year and stratified by sex 
and sexual behavior, age, and race/ethnicity.
Results—During 2009–2013, the proportion of sexually active HIV-infected adults in medical 
care who were tested in the past year for all three examined STDs increased from 20% to 36% 
(PTREND < 0.01). Overall testing for syphilis increased from 55% to 65% (PTREND < 0.01), and 
significant increases were noted for the following subgroups: MSM (58% to 69%), non-Hispanic 
whites (48% to 64%), and all age groups with the exception of 18–29 year olds. Overall testing for 
chlamydia and gonorrhea increased from 22% to 42% (PTREND < 0.01) and significant increases 
were noted for most sub-groups.
Conclusions—STD testing significantly increased among sexually active HIV-infected adults 
receiving medical care; however, the majority of persons were not tested for all three STDs in 
2013. While increased testing indicates progress, testing remained far below recommended 
guidelines. Our findings suggest enhanced efforts may be warranted to screen all sexually active 
HIV-infected adults for syphilis, chlamydia, and gonorrhea.
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At the end of 2013, it was estimated that 933,941 persons were living with diagnosed HIV 
infection in the United States.[1] The Centers for Disease Control and Prevention estimates 
that nearly 20 million cases of sexually transmitted diseases (STD) occur every year in the 
United States, and for the first time since 2006, cases of syphilis, chlamydia and gonorrhea 
increased in 2014. [2] However, national data on HIV and STD co-infection are limited. In 
2014, 26 states reported information about the person’s HIV status in STD cases and the sex 
of their sex partners in at least 70% of primary and secondary syphilis cases.[2] HIV and 
STD co-infection was high, particularly for men who have sex with men (MSM). Among 
primary and secondary syphilis cases with known HIV-status, over half of reported cases 
from MSM were HIV-positive.[2] In addition, among MSM visiting STD Surveillance 
Network (SSuN) sites, the prevalence of syphilis, gonorrhea, and chlamydia were higher 
among MSM living with HIV than among HIV-negative MSM.[2] HIV-infected persons 
who acquire STDs may be at increased risk of developing complications [3] and some STDs 
increase the likelihood of HIV transmission. [4–6] Therefore, STD diagnosis, treatment and 
prevention services are an important part of HIV medical care and can have significant 
public health benefits.[3, 7, 8]
Current guidelines, which have remained largely unchanged since 2004, recommend that 
HIV-infected persons be screened at the time of HIV care initiation and sexually active 
persons be screened at least annually for syphilis, chlamydia, and gonorrhea; however, 
studies suggest that testing is below recommended levels. A recent study that examined STD 
testing among HIV-infected persons in a large health claims database found that 51% of 
privately insured persons were tested for syphilis, 22% for chlamydia, and 22% for 
gonorrhea.[15] A population-based analysis of HIV-infected adults receiving medical care in 
2009 found 55% were tested at least once in the past 12 months for syphilis, and 23% and 
24% received at least one gonorrhea and chlamydia test, respectively.[16] However, 
population-based information on trends in STD testing among HIV-infected persons is 
lacking and of particular importance given the recent increase in STDs. The objective of this 
analysis is to examine temporal trends in STD testing among sexually active HIV-infected 
adults receiving medical care in the United States.
METHODS
We analyzed the most recent available data from the Medical Monitoring Project (MMP), 
(i.e., 2009–2013 cycles) an HIV surveillance system designed to produce nationally 
representative, cross-sectional estimates of behavioral and clinical characteristics of HIV-
infected adults receiving medical care in the United States. MMP methods–including 
sampling, weighting procedures, and response rates have been described in detail elsewhere 
[17, 18]. Briefly, during 2009–2013, MMP utilized a three-stage, complex sampling design 
in which U.S. states and territories were sampled, followed by facilities providing outpatient 
HIV medical care in those jurisdictions, then HIV-infected adults (aged 18 years and older) 
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receiving care in those facilities. All sampled states and territories participated in MMP. 
During 2009 to 2013, facility response rates ranged from 76–85%, and patient response rates 
ranged from 49–55%. Eligible persons were HIV-infected, aged 18 years or older, and had 
received medical care in participating facilities between January and April in the cycle year 
for which they were sampled. Data were collected from June 2009 through May 2014 using 
face-to-face or telephone interviews and medical record abstractions. Data were weighted on 
the basis of known probabilities of selection at state or territory, facility, and patient levels 
[19]. In addition, predictors of nonresponse were determined from analysis of data from 
sampled facilities and patients, and data were then weighted to adjust for non-response, 
following established methods [20, 21].
In accordance with the federal human subjects protection regulations [22] and guidelines for 
defining public health research [23], MMP was determined to be a non-research, public 
health surveillance activity used for disease control program or policy purposes. 
Participating states or territories and facilities obtained local institutional review board 
approval to conduct MMP if required locally. Informed consent was obtained from all 
interviewed participants.
Definitions
We used medical record data to estimate the prevalence of syphilis, chlamydia, and 
gonorrhea testing in the 12 months prior to interview. Syphilis testing was defined as a result 
from non-treponemal or treponemal syphilis test, antibody test, or dark-field microscopy. 
Chlamydia testing was defined as at least one test result from culture, direct fluorescent 
antibody, enzyme immunoassay or enzyme-linked immunoassay, nucleic acid amplification 
test (NAAT), or nucleic acid probe. Testing for gonorrhea was defined as documentation of 
at least one test result from culture, gram stain, NAAT, or the nucleic acid probe. The 
analysis was limited to persons who reported sexual activity in the past 12 months. We 
performed stratified analyses according to the sex of participants and their sex partners in the 
past 12 months (hereafter referred to as sexual behavior). Men who had sex with men only 
or with men and women were defined as MSM; men who had sex with women only were 
defined as MSW; women who had sex with men were defined as WSM. Race/ethnicity was 
defined by self-identification as black or African American, non-Hispanic; Hispanic; or 
white, non-Hispanic. Due to small sample sizes, people who reported other or multiple race/
ethnicities were combined into a single group (hereafter referred to as other race/ethnicity).
We estimated weighted percentages of persons tested for: 1) syphilis and 2) both chlamydia 
and gonorrhea in the last 12 months. We estimated each of these two outcomes separately by 
year and stratified by sexual behavior, age group, and race/ethnicity. We also estimated the 
weighted percentages of persons tested for all three STDs (syphilis, chlamydia, and 
gonorrhea). We calculated percent change in each outcome from 2009–2013 and used 
bivariate linear regression to estimate linear trends over time in each outcome, overall and by 
patient characteristics. Beta coefficients for year represent the average percentage point 
change (divided by 100) from one year to the next. All analyses accounted for the complex 
sample design and weights.
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From 2009 to 2013, the proportion of sexually active, HIV-infected adults in medical care 
tested for syphilis increased from 55% to 65% (β=0.022, PTREND< 0.01). (Figure 1). The 
significant, increasing linear trend in syphilis testing from 2009–2013 was found for some, 
but not all subgroups (Table 1). Testing increased significantly among MSM (58% to 69%, 
β=0.026, PTREND< 0.01) but not among MSW (54% to 61%, β=0.016, PTREND= 0.20) or 
WSM (50% to 59%, β=0.018, PTREND = 0.15). Significant, increasing linear trends in 
syphilis testing were found for all age groups with the exception of people aged 18–29 (60% 
to 66%, β=0.007, PTREND = 0.57). By age, the largest percent change was found among 
persons aged 30–39 years old (57% to 71%, β= 0.023, PTREND = 0.01). Testing increased 
significantly among white, non-Hispanics (48% to 64%, β=0.036, PTREND < 0.01), but not 
among black, non-Hispanics (58% to 64%, β=0.013, PTREND = 0.25), Hispanics (61% to 
69%, β=0.014, PTREND = 0.14), or persons of other race/ethnicity (55% to 60%, β=0.021, 
PTREND = 0.30).
Chlamydia and gonorrhea testing
From 2009 to 2013, the proportion of sexually active, HIV-infected adults in medical care 
tested for chlamydia and gonorrhea increased from 22% to 42% (β= 0.040, PTREND < 0.01). 
(Figure 1). There were significant, increasing linear trends in chlamydia and gonorrhea 
testing from 2009–2013 in every sub-group apart from persons of other race/ethnicity (Table 
2). While chlamydia and gonorrhea testing increased for WSM (27% to 45%, β=0.039, 
PTREND < 0.01), the percent change was larger for MSM (22% to 43%, β=0.051, PTREND < 
0.01) and MSW (17% to 38%, β=0.049, PTREND < 0.01). By age, the largest changes in 
percent tested for chlamydia and gonorrhea were among older age groups. Among 40–49 
year olds, testing increased from 21% to 43% (β=0.054, PTREND < 0.01) and among persons 
50 or older, testing increased from 18% to 36% (β=0.046, PTREND < 0.01). By race/
ethnicity, the largest percent change in chlamydia and gonorrhea testing was among 
Hispanics (26% to 54%, β=0.062, PTREND < 0.01), but the increase was also significant 
among white, non-Hispanics (18% to 36%, β=0.044, PTREND < 0.01) and black, non-
Hispanics (24% to 42%, β=0.045, PTREND < 0.01). The increase in chlamydia and 
gonorrhea testing among persons of other race/ethnicity was not significant (29% to 36%, 
β=0.026, PTREND = 0.11).
Syphilis, chlamydia, and gonorrhea testing
The proportion of sexually active HIV-infected adults tested for all three STIs (syphilis, 
chlamydia, and gonorrhea) increased from 20% to 36% (β=0.040, PTREND < 0.01). (Figure 
1).
DISCUSSION
We found significant increases in testing for syphilis, for chlamydia and gonorrhea, and for 
all three infections among sexually active HIV-infected adults receiving medical care in the 
United States from 2009–2013. However, these increases were not found among all sub-
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groups. While testing for syphilis increased overall from 55% to 65%, the increase was 
significant only among MSM, persons aged 30 years and older, and white, non-Hispanics. 
Notably, the largest percent change occurred among white, non-Hispanics who had the 
lowest levels of syphilis testing in 2009. In contrast, we found significant increases in 
chlamydia and gonorrhea testing overall from 22% to 42% and in nearly every sub-group 
examined. In general, the largest percent change in chlamydia and gonorrhea testing from 
2009 to 2013 occurred among groups with low levels of testing in 2009 (i.e., MSW and 
persons over 30 years of age). However, this was not observed by race/ethnicity. Hispanics 
had comparatively high levels of chlamydia and gonorrhea testing in 2009, yet still had the 
largest percent change. We did not identify a significant increase in chlamydia and 
gonorrhea testing among persons with other race/ethnicity; however, this is likely due to 
small sample size in this group.
Despite the fact that chlamydia and gonorrhea incidence is substantially higher than 
incidence of syphilis, we found that the prevalence of syphilis testing was higher than testing 
for chlamydia and gonorrhea overall, for all sub-groups, and at all time points. In the United 
States in 2014, reported case rates were 456.1 per 100,000 persons for chlamydia, 110.7 per 
100,000 persons for gonorrhea, and 6.3 per 100,000 persons for syphilis.[2] During 2000–
2014, there was an increase in reported syphilis cases, which was primarily attributable to 
increased cases among men, specifically, among MSM.[2] However, during 2013–2014, the 
rate increased among men and among women.[2] More syphilis testing compared to other 
STD testing among HIV-infected persons has been noted in several studies [15, 24] and as 
Hoover et al reported, it is likely attributable to several factors. First, given recent increases 
in syphilis, especially among MSM, [25, 26] patient and provider awareness of the 
importance of syphilis screening may contribute to increased testing. In addition, because 
syphilis infection increases HIV viral load and decreases CD4 cell count in HIV-infected 
persons, failure to treat syphilis could result in increased risk of HIV transmission.[27–29] 
Finally, as a measure of quality assurance, syphilis testing is a requirement of Ryan White 
funding and approximately 73% of MMP facilities received Ryan White funding in 2009–
2011.[30]
While increases in STD testing indicate improvement, testing remains far below 
recommended guidelines, which state that all sexually active HIV-infected persons should be 
screened at least annually for syphilis, chlamydia and gonorrhea. Possible reasons why 
providers are not adherent to recommended guidelines include time constraints, the 
invasiveness of some screening tests, or personal discomfort discussing sexual behavior.[31, 
32] However, effective interventions exist to increase provider’s adherence to guidelines as 
well as patients’ acceptance of screening. Examples of effective tools include electronic 
alerts for doctors; syphilis serology included with blood tests performed as part of HIV 
monitoring, educational workshops for clinic staff; internet-based continuing medical 
education; free sexual health consultations for patients; biannual STD testing, coupled with 
brief risk-reduction counseling; and provision of a urine specimen cup at the time of patient 
registration.[33–35] These strategies could be used to increase routine STD screening.
This analysis has limitations. First, our estimates may underestimate STD testing in HIV 
positive persons in care because we only collected data from the medical record at the 
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persons’ primary HIV care provider, which could miss STD testing that occurred outside of 
that setting. Second, MMP altered the way STD testing information was captured in 2013 
such that it was easier to record tests at multiple anatomical sites on the same day; however, 
all trends remained significant when we limited the analysis to 2009–2012 data only (data 
not shown). Third, we were unable to determine if STD tests were administered as part of 
regular screening, as guidelines recommend, or due to the presence of symptoms. Fourth, 
while patients were randomly sampled each year, it is possible that a person was selected 
and participated in more than one data collection cycle. Our analysis did not account for this 
correlation. However, we replicated the analysis with such patients removed and results of 
all trend analyses remained unchanged. Lastly, during 2009–2013, MMP included only 
people who were receiving HIV medical care; therefore, our estimates are unlikely to be 
generalizable to all HIV-diagnosed persons in the U.S.
From 2009 to 2013, testing for syphilis, chlamydia, and gonorrhea increased among sexually 
active HIV-infected persons receiving HIV medical care in the United States. However, in 
2013 64% of persons did not receive recommended testing for all three STDs. Further, 
syphilis testing did not increase among MSW, WSM, those aged 18–29, blacks, non-
Hispanics or Hispanics. Given that syphilis case rates have increased among MSM, MSW, 
and women in recent years and the fact that racial disparities exist, the failure to identify 
increased syphilis testing among all groups indicates a need for improvement. Moreover, 
these suboptimal testing rates are likely to be even lower among persons not receiving HIV 
medical care. Given the morbidity associated with STDs and their potential to increase HIV 
transmission, our findings suggest that enhanced efforts may be warranted to screen all HIV-
infected sexually active adults for syphilis, chlamydia, and gonorrhea at all appropriate 
anatomical sites.
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